What ALDER BIOPHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Montgomery Alan Bruce | Director | Oct 22 | Tender Offer · U | −9,628 | $18.00 | −$173K | 0 |
| Redmile Group, Llc | Director | Oct 22 | Tender Offer · U | −8,244,896 | — | — | 0 |
| Lavelle Erin | Chief Operating Officer | Oct 22 | Tender Offer · U | −16,092 | $18.00 | −$290K | 0 |
| Lavelle Erin | Chief Operating Officer | Oct 22 | Grant / award · A | +11,684 | — | — | 16,092 |
| Yarno Wendy L | Director | Oct 22 | Tender Offer · U | −5,000 | $18.00 | −$90K | 0 |
| Siegall Clay B | Director | Oct 22 | Tender Offer · U | −31,714 | $18.00 | −$571K | 0 |
| H Lundbeck A S | 10% owner | Oct 22 | Open-market buy · P | +85,923,561 | — | — | 0 |
| Hassler Randal | EVP, Pharmaceutical Ops. | Oct 22 | Disposition to Issuer · D | −19,780 | $18.00 | −$356K | 0 |
| Hassler Randal | EVP, Pharmaceutical Ops. | Oct 22 | Grant / award · A | +14,346 | — | — | 19,780 |
| Bucher James B | EVP & General Counsel | Oct 22 | Tender Offer · U | −27,677 | $18.00 | −$498K | 0 |
| Bucher James B | EVP & General Counsel | Oct 22 | Grant / award · A | +15,619 | — | — | 27,677 |
| Smith Jeffrey T L | Managing Director | Oct 22 | Disposition to Issuer · D | −21,502 | $18.00 | −$387K | 0 |
| Smith Jeffrey T L | Managing Director | Oct 22 | Grant / award · A | +16,230 | — | — | 21,502 |
| Streck Paul | Chief Medical Officer | Oct 22 | Disposition to Issuer · D | −1,390 | $18.00 | −$25K | 0 |
| Bucher James B | EVP & General Counsel | Oct 11 | Grant / award · A | +904 | $9.20 | +$8.32K | 12,058 |
| Streck Paul | Chief Medical Officer | Oct 11 | Grant / award · A | +1,390 | $9.20 | +$12.8K | 1,390 |
| Smith Jeffrey T L | Managing Director | Sep 16 | Disclosed 10b5-1 sale · S | −32,728 | $18.44 | −$604K | 5,272 |
| Smith Jeffrey T L | Managing Director | Sep 16 | Exercise / conversion · M | +10,001 | $3.47 | +$34.7K | 38,000 |
| Smith Jeffrey T L | Managing Director | Sep 16 | Exercise / conversion · M | +22,727 | $4.46 | +$101K | 27,999 |
| Bucher James B | EVP & General Counsel | May 31 | Grant / award · A | +1,345 | $9.20 | +$12.4K | 11,154 |
Loading...
